1. Introduction {#sec1-ijms-21-04120}
===============

Recurrent arterial or venous thrombosis and/or obstetric morbidity in the presence and persistence of antiphospholipid antibodies (aPL) detected via immunoassays or clotting tests characterise the antiphospholipid syndrome (APS): APS may be isolated (primary APS, PAPS) or associated with other autoimmune disease (secondary APS), the most common being represented by systemic lupus erythematosus (SLE, lupus-related APS) \[[@B1-ijms-21-04120]\]. Autoimmune haemolytic anaemia (AIHA) develops when antibodies of the host immune system attack autologous red blood cells, usually demonstrated by a positive direct antiglobulin test (DAT), decreasing the patient's life span and leading to haemolysis. Further, depending on the temperature at which the antibody-red cell reaction occurs, the antibodies can be defined as warm or cold (reviewed in \[[@B2-ijms-21-04120]\]). AIHA with a positive DAT is part of the haematological domain of the EULAR/ACR classification criteria for SLE \[[@B3-ijms-21-04120]\] whereas either an AIHA or a positive DAT in the absence of anemia are part of the clinical and laboratory criteria for SLE \[[@B4-ijms-21-04120]\]. Conversely, AIHA is not part of the criteria for sero-positive or sero-negative APS \[[@B5-ijms-21-04120]\]. We therefore performed a systematic review and meta-analysis to evaluate the extent of the relationship between aPL and AIHA, and the results are presented herein.

2. Results {#sec2-ijms-21-04120}
==========

2.1. Number of Included Studies {#sec2dot1-ijms-21-04120}
-------------------------------

After completion of the screening and exclusion process ([Figure 1](#ijms-21-04120-f001){ref-type="fig"}), we identified 59 articles \[[@B6-ijms-21-04120],[@B7-ijms-21-04120],[@B8-ijms-21-04120],[@B9-ijms-21-04120],[@B10-ijms-21-04120],[@B11-ijms-21-04120],[@B12-ijms-21-04120],[@B13-ijms-21-04120],[@B14-ijms-21-04120],[@B15-ijms-21-04120],[@B16-ijms-21-04120],[@B17-ijms-21-04120],[@B18-ijms-21-04120],[@B19-ijms-21-04120],[@B20-ijms-21-04120],[@B21-ijms-21-04120],[@B22-ijms-21-04120],[@B23-ijms-21-04120],[@B24-ijms-21-04120],[@B25-ijms-21-04120],[@B26-ijms-21-04120],[@B27-ijms-21-04120],[@B28-ijms-21-04120],[@B29-ijms-21-04120],[@B30-ijms-21-04120],[@B31-ijms-21-04120],[@B32-ijms-21-04120],[@B33-ijms-21-04120],[@B34-ijms-21-04120],[@B35-ijms-21-04120],[@B36-ijms-21-04120],[@B37-ijms-21-04120],[@B38-ijms-21-04120],[@B39-ijms-21-04120],[@B40-ijms-21-04120],[@B41-ijms-21-04120],[@B42-ijms-21-04120],[@B43-ijms-21-04120],[@B44-ijms-21-04120],[@B45-ijms-21-04120],[@B46-ijms-21-04120],[@B47-ijms-21-04120],[@B48-ijms-21-04120],[@B49-ijms-21-04120],[@B50-ijms-21-04120],[@B51-ijms-21-04120],[@B52-ijms-21-04120],[@B53-ijms-21-04120],[@B54-ijms-21-04120],[@B55-ijms-21-04120],[@B56-ijms-21-04120],[@B57-ijms-21-04120],[@B58-ijms-21-04120],[@B59-ijms-21-04120],[@B60-ijms-21-04120],[@B61-ijms-21-04120],[@B62-ijms-21-04120],[@B63-ijms-21-04120],[@B64-ijms-21-04120]\] exploring the relationship between aPL and AIHA/DAT ([Table 1](#ijms-21-04120-t001){ref-type="table"}) that were included in the qualitative survey. Of these, four were not included in the meta-analysis because three did not share common outcomes with other studies \[[@B14-ijms-21-04120],[@B17-ijms-21-04120],[@B29-ijms-21-04120]\] (one presented mean and standard deviations of the aPL titres) \[[@B29-ijms-21-04120]\] and one presented differential data regarding AIHA in arterial and venous thrombosis that we were not able to discriminate \[[@B42-ijms-21-04120]\].

2.2. Clinical Definitions {#sec2dot2-ijms-21-04120}
-------------------------

Of 15 articles having AIHA/DAT as their main topic, 10 provided a clear definition of AIHA \[[@B9-ijms-21-04120],[@B19-ijms-21-04120],[@B29-ijms-21-04120],[@B46-ijms-21-04120],[@B47-ijms-21-04120],[@B49-ijms-21-04120],[@B53-ijms-21-04120],[@B57-ijms-21-04120],[@B61-ijms-21-04120]\] whereas five provided an incomplete or no definition of AIHA \[[@B43-ijms-21-04120],[@B48-ijms-21-04120],[@B62-ijms-21-04120],[@B64-ijms-21-04120]\]. Further, of 42 articles not having AIHA as their main topic, only nine provided a clear definition.

Within the text, we make reference to the pooled prevalence of AIHA, DAT, APL, and thrombosis. This should be intended as pooled prevalence of patients with the given clinical or laboratory feature, but we left the term pooled prevalence to avoid the continuous repetition of the same sentence.

2.3. Comparative Prevalence of Antiphospholipid Antibodies in Patients with and without Autoimmune Haemolytic Anaemia {#sec2dot3-ijms-21-04120}
---------------------------------------------------------------------------------------------------------------------

Nine articles comprising 456 AIHA +ve and 3951 AIHA −ve patients explored the relationship between IgG anticardiolipin (aCL) and AIHA in SLE. The PP of IgG aCL was slightly higher in AIHA +ve than AIHA −ve groups (34.6% vs. 28.3%) with mild heterogeneity (*I*^2^ = 24%, *p* = 0.2) ([Figure 2](#ijms-21-04120-f002){ref-type="fig"}A). Eight articles comprising 391 AIHA +ve and 3387 AIHA −ve patients explored the relationship between IgM aCL and AIHA in SLE. The PP of IgM aCL was slightly higher in AIHA +ve than AIHA −ve groups (36% vs. 22%) with wide heterogeneity (*I*^2^ = 80%, *p* \< 0.0001) ([Figure 2](#ijms-21-04120-f002){ref-type="fig"}B). Six articles comprising 262 AIHA +ve and 2129 AIHA −ve patients explored the relationship between LA and AIHA in SLE. The PP of LA was greater in AIHA ve than AIHA −ve groups (20.9% vs. 8.3%) with wide heterogeneity (*I*^2^ = 91%, *p* \< 0.001 ([Figure 2](#ijms-21-04120-f002){ref-type="fig"}C). Three articles explored the relationship between IgG aCL and idiopathic AIHA, comprising 58 AIHA +ve and 66 AIHA −ve patients; the pooled prevalence of patients with IgG aCL was greater in the AIHA +ve than AIHA −ve group (22.4% vs. 3.3%) ([Figure A2](#ijms-21-04120-f0A2){ref-type="fig"}).

2.4. Comparative Prevalence of Antiphospholipid Antibody in Patients with and without a Positive Coombs Test {#sec2dot4-ijms-21-04120}
------------------------------------------------------------------------------------------------------------

Three articles comprising 99 DAT +ve and 397 DAT −ve patients explored the relationship between IgG aCL and DAT in SLE. The PP of IgG aCL was much greater in DAT +ve than DAT −ve groups (42.4% vs. 12.8%) ([Figure 3](#ijms-21-04120-f003){ref-type="fig"}A). Three articles comprising 99 DAT +ve and 397 DAT −ve patients explored the relationship between IgM aCL and DAT in SLE. The PP of IgM aCL was greater in DAT +ve than DAT −ve groups (26.2% vs. 12.8%) ([Figure 3](#ijms-21-04120-f003){ref-type="fig"}B). Three articles comprising 65 DAT +ve and 526 DAT −ve patients explored the relationship between LA and DAT in SLE. The PP of LA was higher in AIHA +ve than AIHA −ve groups (29.2% vs. 15.7%) ([Figure 3](#ijms-21-04120-f003){ref-type="fig"}C).

2.5. Comparative Prevalence of Autoimmune Haemolytic Anaemia in Patients with and without Antiphospholipid Antibodies {#sec2dot5-ijms-21-04120}
---------------------------------------------------------------------------------------------------------------------

Ten articles comprising 352 IgG aCL +ve and 664 IgG aCL −ve SLE patients explored the relationship between AIHA and IgG aCL in SLE. The PP of AIHA was higher in IgG aCL +ve than −ve groups (21.8% vs. 11.1%) with low heterogeneity (*I*^2^ = 20%, *p* = 0.2) ([Figure 4](#ijms-21-04120-f004){ref-type="fig"}A). Five studies comprising 139 IgM aCL +ve and 888 IgM aCL −ve patients explored the relationship between AIHA and IgM aCL in SLE. The PP of AIHA was higher in IgM aCL +ve than −ve groups (18.7% vs. 6.3%) with low heterogeneity (*I*^2^ = 25%, *p* = 0.2) ([Figure 4](#ijms-21-04120-f004){ref-type="fig"}B). Two articles comprising 39 IgM aCL +ve and 69 IgG aCL −ve in PAPS explored the same relationship in PAPS. The PP of AIHA between IgG aCL +ve and −ve groups was similar (12.8% vs. 7.2%) with no heterogeneity. Four studies comprising 75 IgG aβ~2~GPI +ve and 447 IgG aβ~2~GPI −ve patients explored the relationship between AIHA and IgG aβ~2~GPI. The PP of AIHA was higher in IgG aβ~2~GPI +ve than −ve groups (18.6% vs. 7.1%) with wide heterogeneity (*I*^2^ = 58%, *p* = 0.6) ([Figure A3](#ijms-21-04120-f0A3){ref-type="fig"}). Five articles comprising 271 LA +ve and 950 LA −ve patients explored the relationship between AIHA and LA. The PP of AIHA was greater in LA +ve than LA −ve groups (20% vs. 10%) with mild heterogeneity (*I*^2^ = 29%, *p* = 0.25) ([Figure A4](#ijms-21-04120-f0A4){ref-type="fig"}).

2.6. Comparative Prevalence of Coombs Test in Patients with and without Antiphospholipid Antibodies {#sec2dot6-ijms-21-04120}
---------------------------------------------------------------------------------------------------

Five articles comprising 446 IgG aCL +ve and 417 IgG aCL −ve patients explored the relationship between DAT and IgG aCL. The PP of DAT was higher in IgG aCL +ve than −ve groups (33.6% vs. 11.9%) with wide heterogeneity (*I*^2^ = 72%, *p* = 0.006) ([Figure A5](#ijms-21-04120-f0A5){ref-type="fig"}). Three articles comprising 51 LA +ve and 117 LA −ve patients explored the relationship between DAT and LA. The PP of AIHA was much higher in LA +ve than −ve groups 27.4% vs. 5.1%, *p* \< 0.05) ([Figure A6](#ijms-21-04120-f0A6){ref-type="fig"}).

2.7. Comparative Prevalence of Autoimmune Haemolytic Anaemia and Coombs Test in Relation to Primary and Lupus Related Antiphospholipid Syndrome and to any Thrombosis {#sec2dot7-ijms-21-04120}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Seven articles comprising 482 SLE related and 729 PAPS patients explored the relationship between AIHA and APS. The PP of AIHA was higher in SLE related than in PAPS (22.8% vs. 3.7%) with wide heterogeneity (*I*^2^ = 67%, *p* = 0.006) ([Figure 5](#ijms-21-04120-f005){ref-type="fig"}A). Two articles comprising 41 aPL carriers and 91 primary APS patients explored the relationship between AIHA and APS. The PP of AIHA was higher in aPL carriers than in PAPS (19% vs. 5.4%). Five articles comprising 379 SLE with thrombotic APS and 1117 SLE without thrombosis explored the relationship between AIHA and thrombosis in SLE. The PP of AIHA was greater in APS +ve than APS −ve SLE (23.2% vs. 8.4%) with wide heterogeneity (*I*^2^ = 72%, *p* \< 0.0001) due to two studies that over-favored the effect size ([Figure 5](#ijms-21-04120-f005){ref-type="fig"}B). Four articles comprising 123 aPL positive SLE patients with and 607 without any vascular occlusion explored the relationship between AIHA and thrombosis. The PP of AIHA was higher in the thrombotic than the non-thrombotic group (26.8% vs. 10%) with medium heterogeneity (*I*^2^ = 40%, *p* = 0.1 ([Figure 5](#ijms-21-04120-f005){ref-type="fig"}C). Three articles comprising 143 SLE carriers of aPL and 93 PAPS patients explored the relationship between DAT and APS. The PP of DAT was higher in SLE carriers of aPL than in primary APS (37.7% vs. 16%) (*I*^2^ = 70%, *p* = 0.04) ([Figure A7](#ijms-21-04120-f0A7){ref-type="fig"}).

3. Discussion {#sec3-ijms-21-04120}
=============

The studies included in the systematic review were evaluated according to two complementary scenarios. In the first scenario, we determined the PP of aPL positive patients in AIHA, whether SLE related or idiopathic, and in the second scenario we determined the PP of AIHA in patients with aPL, whether affected by SLE and/or APS.

According to the first scenario, the pooled prevalence of patients positive for IgG/IgM aCL and LA were all greater in SLE with AIHA, with a degree of statistical heterogeneity explained by the occasional outlier that favored the effect size in each study. Conversely, the studies on idiopathic AIHA were devoid of heterogeneity. According to the second scenario, AIHA was more common in SLE patients positive for IgG aCL and IgM aCL but less for IgG aβ~2~GPI: AIHA was also more common in LA positive SLE patients with no heterogeneity as in the two complementary studies assessing the relation between DAT and LA. Because of its fluid phase nature, LA may detect a wider repertoire of antibodies than the solid phase immune assay that detects a single antibody, although in both scenarios, IgG/IgM aCL and DAT showed strong reciprocal effect sizes. Altogether, these findings suggest that a clinical manifestation such as AIHA relates prevalently to IgG aCL whereas a laboratory manifestation such as a DAT relates strongly to all aPL.

The varied definitions of AIHA adopted by the authors, the presence of DAT negative patients \[[@B65-ijms-21-04120]\] in few studies may explain some of the observed clinical heterogeneity, though even DAT negative cases may be caused by warm IgM auto-antibodies identifiable by the dual direct antiglobulin test \[[@B66-ijms-21-04120]\]. Alternatively, patients with aPL/APS may yield false positive DATs \[[@B67-ijms-21-04120]\] due to cytophilic or non-specifically adsorbed IgG on the surface of erythrocytes, the eluates of which do not contain any antibody \[[@B68-ijms-21-04120]\]. In SLE, DAT predicts 8-epi-prostaglandin-F2α, a specific marker of lipid peroxidation \[[@B69-ijms-21-04120]\]. In the oxidative environment of SLE and APS \[[@B69-ijms-21-04120],[@B70-ijms-21-04120]\], phospatidylcholine and phosphatidylserine present in the erythrocyte membrane may oxidise contributing to erythrocyte senescence \[[@B71-ijms-21-04120],[@B72-ijms-21-04120]\]: natural IgM autoantibodies may perform housekeeping functions against these phospholipid neo-epitopes \[[@B73-ijms-21-04120]\] but the intra-splenic clearance of senescent erythrocytes is normally mediated by antibody-independent mechanisms, such as the recognition of phosphatidylserine exposed on the outer leaflet of their plasmamembrane by macrophage scavenger receptors \[[@B74-ijms-21-04120]\]. Participation of natural IgM bound to oxidised PS (oxPS) would require complement activation and recognition of iC3b by CR3 and CR4 complement receptors: neither "true" Fc receptors for the IgM isotype, nor mixed Fc receptors for the IgA and IgM isotypes are expressed by human macrophages. On the other hand, natural IgM antibodies bound to oxidized phospholipids may prevent the activation of pro-inflammatory responses of phagocytes via scavenger receptors, such as CD36, CD68, SR-PSOX; these natural antibodies may cross react with aPL as eluates from the erythrocyte of SLE patients with aPL revealed strong cardiolipin \[[@B75-ijms-21-04120]\] and oxidated phospatidylcholine reactivity \[[@B76-ijms-21-04120]\].

Also, the relation between AIHA and thrombosis also offers several scenarios: AIHA was much more common in SLE related APS than in SLE without APS or PAPS. However, these studies comprised not only patients with thrombosis but also patients with obstetric morbidity, the presence of which may have weakened the effect size between AIHA and thrombosis. Nevertheless, there was a greater PP of AIHA in thrombotic rather than non-thrombotic SLE patients and to complete this scenario also the DAT was more common in SLE related APS than PAPS.

The relationship between aPL and AIHA may rely on several different mechanisms related to erythrocyte antigenicity. These may be either proteins/glycoproteins or carbohydrate moieties positioned on glycoproteins and glycolipids \[[@B77-ijms-21-04120]\]: proteins/glycoprotein moieties induce IgG1 and IgG3 subclass response which is T-cell-dependent, whereas carbohydrate moieties induce mostly an IgG2 subclass response which is T-cell-independent \[[@B78-ijms-21-04120],[@B79-ijms-21-04120],[@B80-ijms-21-04120]\].

Shortened erythrocyte survival also depends upon the IgG subclass: IgG1 followed by IgG3 are more efficient than IgG2 and IgG4: the former bind avidly to C1q and are strong complement activators, IgG2 is a poor complement activator, and IgG4 does not activate complement because it does not bind to C1q \[[@B81-ijms-21-04120]\]. In APS, the IgG2 and the IgG3 subclasses \[[@B82-ijms-21-04120]\] are strongly associated with thrombosis \[[@B83-ijms-21-04120],[@B84-ijms-21-04120]\].

Once reached a critical amount on the erythrocyte membrane aPL may activate complement leading to erythrocyte destruction; with regards to hemolysis the effect size was always greater for IgM aCL than for IgG aCL, in keeping with the fact that the IgM isotype is a powerful complement activator, to an even higher extent than the most abundant IgG1 and IgG2 isotypes, but it is not usually found on the erythrocyte surface by DAT in warm AIHA. Low serum complement occurs in 38% of SLE but only in 9% of primary APS patients and it is associated with AIHA in SLE related but not in PAPS \[[@B84-ijms-21-04120]\]. Compared to normal and thrombotic controls, patients with SLE related APS display a higher amount of erythrocyte bound C4d \[[@B85-ijms-21-04120]\]. Moreover, the annexin V binding test revealed that almost 50% of SLE erythrocytes express phosphatidylserine on their surface that is known to support thrombin generation in vitro \[[@B75-ijms-21-04120]\].

Coagulation and complement functions may proceed simultaneously in APS \[[@B86-ijms-21-04120]\]. As part of this cross talk, C5a engages its counter receptor on neutrophils and induces tissue factor release \[[@B87-ijms-21-04120]\] that in turn catalyzes factor X to its active form promoting thrombin generation, whereas downstream of C5a, the C5b--9 membrane attack complex induce platelet and endothelial cell activation \[[@B81-ijms-21-04120]\].

However, we must remember that intravascular hemolysis mediated by the terminal complement pathway is not as prominent as reticulo-endothelial cell phagocytosis of C3b opsonized erythrocytes, that is the main mechanism for warm autoimmune haemolysis.

Summing up the above scenarios it is likely that classical and alternative complement pathways as well as coagulation activation occur in SLE with APS and thrombosis, while complement activation on its own occurs in SLE with or without aPL and coagulation activation only in APS. This would explain the decreasing frequency of AIHA through the three conditions mentioned, though there is recent evidence that complement activation may also occur in APS \[[@B88-ijms-21-04120]\].

Limitations of our meta-analysis include: (1) variability in study sizes, (2) few studies on PAPS, (3) expression of data as frequency of aPL positive participants rather than average antibody titres in most articles, and hence (4) no relation between aPL titers with severity of haemolysis or intensity of DAT positivity, as well as (5) a lack of follow up in patients with isolated DAT positivity to verify whether they do develop AIHA.

Nevertheless, our meta-analysis clearly demonstrates an intimate relationship between aPL and AHIA: the pooled prevalence of patients with AIHA ranges between 23% and 26% in SLE with APS, not much different from the 22.4% deriving from a meta-analysis published in abstract form in 2015 \[[@B89-ijms-21-04120]\]. Likewise, our 8.4% PP from our aPL +ve SLE patients equals the PP of their aPL −ve patients, probably because the authors included amongst their SLE related APS also aPL +ve patients. Once split into individual aPL, their OR for LA was 4.58 (95% CI 2.62--8.04), ours was twice as much when comparing the PP of LA in SLE with and without AIHA (OR 8.3, 95% CI 1.52--45.39) whereas the comparative figures for AIHA in LA +ve and LA −ve SLE patients was twice as low (OR 2.10 95% CI 1.38--3.18). Their risk of AIHA in IgG aCL (OR 2.27, 95% CI 1.71--3.00) was slightly higher than ours (OR 2.23, 95% CI 1.41--3.52) whereas their risk of AIHA in IgM (OR 2.89, 95% CI 2.16--3.87) was almost four times lower than ours (OR 8.66, 95% CI 3.68--20.36). These differences are likely due to the different pooling of data and outcomes in our meta-analysis.

Moreover, the 23--26% AIHA in SLE with APS, the 8.4% in SLE with aPL, and the 4% in PAPS, are in keeping with the inclusion of AIHA in the classification criteria for SLE but not for APS. Likewise, the pooled prevalence of DAT associated with aPL in SLE was around 37% but only 16% in PAPS. Interestingly, AIHA predicts mortality in the first year after diagnosis of SLE and during follow up \[[@B90-ijms-21-04120]\] whereas an isolated DAT predicts disease activity \[[@B47-ijms-21-04120],[@B55-ijms-21-04120]\]. Because disease activity relates to oxidative stress \[[@B69-ijms-21-04120]\], the question arises as to whether an isolated DAT, particularly when caused by an IgM, represents a natural or a pathogenic antibody. In fact, the majority of circulating IgM are polyspecific natural auto-antibodies, secreted in a T-cell-independent manner and encoded by multiple germ-line variable region genes, with little somatic mutation and few non-templated insertions; the minority of circulating IgM are immune IgM produced by B cells selected for antigen-specificity, usually following exposure to pathogens \[[@B91-ijms-21-04120]\]. Thus, natural and (auto)immune IgM may coexist in the same individual. To conclude, the meta-analysis finds a consistent relationship between aPL and AHIA (IgM aCL \> IgG aCL \> LA \> IgG aβ~2~GPI) as well as between AIHA and thrombosis, particularly in patients with SLE: while plausible thrombogenic pathways linking AIHA and SLE do exist, the intimate nature of the reaction between different aPL isotypes and erythrocyte structures remains unclear and warrants further research

4. Materials and Methods {#sec4-ijms-21-04120}
========================

4.1. Search Strategy and Selection Criteria {#sec4dot1-ijms-21-04120}
-------------------------------------------

Two authors carried out the systematic review according to the PRISMA guidelines \[[@B92-ijms-21-04120]\] was carried out by two searching the electronic databases MEDLINE and EMBASE from inception to February 2020 for the following terms: "haemolysis" OR "haemolytic anaemia" OR "direct antiglobulin test" OR "direct Coombs test" and "anticardiolipin" OR "anti-beta 2-glycoprotein-I" OR "antiphospholipid syndrome", OR "lupus anticoagulant" OR "lupus inhibitor". The search yielded 3106 records plus another 12 found amongst the references screened for inclusion in the systematic review. The records were fed into EndNote that removed the duplicates leaving 1177 records. The same authors plus a third screened the records for relevancy and excluded 1049 (including 54 dealing with microangiopathic haemolytic anaemia and 59 case reports), thus leaving 128 eligible articles ([Figure 1](#ijms-21-04120-f001){ref-type="fig"})

4.2. Criteria for Selecting Articles {#sec4dot2-ijms-21-04120}
------------------------------------

Inclusion criteria were: (1) case-control and/or cohort observational studies investigating relevant adult populations: (a) the different titers or frequency aPL between patient and control groups with AIHA or with a positive DAT, (b) the different titers or frequency of aPL between AIHA and/or DAT patients positive and negative for AIHA, and (c) the different frequency of AIHA and/or DAT in aPL positive or negative patients; (2) aPL tested by immune or clotting assays; (3) articles written in English, French, and Spanish. We chose the highest-quality study if two or more studies investigated the same population. Exclusion criteria were: (1) prevalence studies only, (2) paediatric populations, (3) catastrophic antiphospholipid syndrome, (4) studies not reporting the relationship between aPL and AIHA, (5) non-original research, (6) articles not written in the languages indicated in the inclusion criteria

4.3. Evaluation of the Quality of the Studies {#sec4dot3-ijms-21-04120}
---------------------------------------------

The Newcastle Ottawa Quality Assessment Scale for case-control and cohort studies was employed to assess the quality of the relevant studies \[[@B93-ijms-21-04120]\]. The final score may range between 0 and 8, and results from the sum of the ratings of three major domains: case/controls selection, their comparability, and ascertainment of their exposure to the outcome of interest.

4.4. Outcome Measures {#sec4dot4-ijms-21-04120}
---------------------

The primary outcomes were: (1) the comparative pooled prevalence (PP) of different aPL in participants with and without AIHA or DAT, (2) the comparative pooled prevalence of AIHA or DAT in participants with and without aPL and the standardized mean difference of aPL titres between the groups indicated in number one and two. The secondary outcomes, where possible, were: (1) the comparative pooled prevalence of vascular occlusions in participants positive or negative for aPL plus AIHA or aPL plus DAT, (2) the pooled prevalence of aPL plus AIHA or aPL plus DAT in participants with or without vascular occlusions, and (3) the standardized mean difference of the titers of aPL between participants with and without AIHA or DAT.

4.5. Statistical Analysis {#sec4dot5-ijms-21-04120}
-------------------------

As all the included studies included had an observational design with no planned exposure, we employed: (1) random effects meta-analyses for categorical outcomes, (2) Peto's odds ratio for rare events to compare the pooled frequencies between groups \[[@B94-ijms-21-04120]\], (3) I^2^ statistics to evaluate statistical heterogeneity. Heterogeneity was nil when I^2^ equaled 0%, low when I^2^ was less than 25%, moderate with I^2^ between 25% and 50% and high with I^2^ greater than 50%. Ten studies having similar outcomes yielded a funnel plot showing a slight publication bias due to imprecise study effect \[[@B95-ijms-21-04120]\] ([Figure A1](#ijms-21-04120-f0A1){ref-type="fig"}) but we did not rely on this result, as funnel plots may be misleading when performed on a small number of studies \[[@B96-ijms-21-04120],[@B97-ijms-21-04120]\]. Comprehensive Meta-Analysis (Biostat, Englewood, New Jersey, USA) was used for the statistical analysis, and the inter-rater agreement of two investigators was assessed by Cohen's kappa.
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###### 

(**A**) Effect size of IgG anticardiolipin, (**B**) IgM anticardiolipin and (**C**) lupus anticoagulant in lupus related autoimmune haemolytic anaemia.
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###### 

Effect size autoimmune haemolytic anaemia in relation to (**A**) primary and lupus with antiphospholipid syndrome (**B**) lupus with and without antiphospholipid syndrome, (**C**) thrombosis in systemic lupus erythematosus.
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###### 

Demographics of studies included in the systematic review and meta-analysis.

  -------------------------- ------------- ---------------- ------------------ -------------- ----------- -------- ----- ----------- --------- -------------- -------------------------- ---------- -------------- --------- --------- --------- --------- -------- ---------
  **(A)**                                                   **Participants**                                                                                                                                                                                        
  **Studies on SLE/APS**                                    **SLE**            **PAPS/APL**   **Other**                                                                                  **aCL**    **aβ~2~GPI**                                                    
  **Reference**              **Country**   **Study Type**   **SLE**            **aPL**        **APS**                    **Total**   **M/F**   **Assessed**   **Age**                    **AIHA**   **DAT**        **IgG**   **IgM**   **IgG**   **IgM**   **LA**   **NOS**
                                                            **No**             **No**         **No**      **No**   No    No          No        No             Mean ± SD/median (range)   No         No             No        No        No        No        No       
  \[[@B6-ijms-21-04120]\]    USA           CHT              180                                                    120   300         19/102    121            34 (17--74)                           27             74                                               7
  \[[@B7-ijms-21-04120]\]    Israel        CHT              36                                                           36          4/32      36             40 ± 19                    8          8                                                      7        6
  \[[@B8-ijms-21-04120]\]    Holland       CHT              74                                                     51    112                   74                                        15                                                                19       6
  \[[@B9-ijms-21-04120]\]    Mexico        CHT              12                                                           12          0/12      12             26 ± 9                                9              7         7                             3        7
  \[[@B10-ijms-21-04120]\]   Canada        CHT              51                 14                                        65          4/61      65             43                         4          4              13                                      10       8
  \[[@B11-ijms-21-04120]\]   Mexico        CHT              500                y              y                          500         50/450    500            34 (12--70)                25                        200       166                                    7
  \[[@B12-ijms-21-04120]\]   Spain         CC               46                 9              5                    107   167         42/125    60                                        4                         14        13                                     6
  \[[@B13-ijms-21-04120]\]   Spain         CHT              88                 y              y                          88                    88                                        14                        28                                      24       5
  \[[@B14-ijms-21-04120]\]   Israel        CHT              15                                                     33    48                    40                                        1          12                                                     40       5
  \[[@B15-ijms-21-04120]\]   Spain         CHT              64                 36                                        100         7/93      100                                       9                         24        20                            30       7
  \[[@B16-ijms-21-04120]\]   Australia     CHT              111                y              y                          111         6/105     111            15--70                                42             31        21                                     6
  \[[@B17-ijms-21-04120]\]   Spain         CHT                                                            23             23          4/19      23             29 ± 8                     3                         11        7                             18       5
  \[[@B18-ijms-21-04120]\]   USA           CHT              32                 20             13                         65          41/24     65             29 ± 12                    16                                                                33       6
  \[[@B19-ijms-21-04120]\]   Singapore     CHT              46                 y                                         46          46 F      46                                        17                        5         11                                     5
  \[[@B20-ijms-21-04120]\]   Japan         CHR              77                 272                                       349                   349                                                  14             41        4                             26       4
  \[[@B21-ijms-21-04120]\]   USA           CHT              139                y              y                          139         32/107    139            33 ± 16                    27                        57                                               7
  \[[@B22-ijms-21-04120]\]   Thailand      CHT              75                 16                                        91                    91                                        4                                                                 14       5
  \[[@B23-ijms-21-04120]\]   MC            CHT                                                56          58             114         22/92     114            34 ± 14                    16         12                                                              7
  \[[@B24-ijms-21-04120]\]   Germany       CHT              124                244                                       368         36/332    368            48 (12--76)                           27             168                                              8
  \[[@B25-ijms-21-04120]\]   Canada        CHT              206                184                                       390         47/343    390            32 (7--83)                            118            184                                              6
  \[[@B26-ijms-21-04120]\]   Japan         CHT              119                21                                        140         16/124    140            34 ± 12                    8                         61                  21                           6
  \[[@B27-ijms-21-04120]\]   Spain         CHT              16                 7                                         23          0/23      23             28                         5          9              7         7                                      6
  \[[@B28-ijms-21-04120]\]   Ireland       CHT              53                 42                                        95          10/85     95             13--70                     4          1              30        27                                     6
  \[[@B29-ijms-21-04120]\]   Germany       CC               96                 y                                   152   248                   96                                        22         22             53 ± 57   28 ± 32                                7
  \[[@B30-ijms-21-04120]\]   USA           CHT              38                 y              10                         48          10/38     28                                        6                         16        10        11        9                  6
  \[[@B31-ijms-21-04120]\]   UK            CHT              78                                40                         118         4/114     118            40 (10--71)                8                                             20                           5
  \[[@B32-ijms-21-04120]\]   MC            CHT              258                80             y                          258         34/224    258            29 (4--70)                 25                        60        20        27        23                 7
  \[[@B33-ijms-21-04120]\]   Europe        MCT              574                y                                         574         44/503    574            38 ± 13                    48                        119       73        110       109                7
  \[[@B34-ijms-21-04120]\]   Spain         CHT                                                38          62             100         14/86     100            36 (13--79)                13                        74        32                                     7
  \[[@B35-ijms-21-04120]\]   Switzerland   CHT                                                86          22             108         14/94     108            42 ± 13                               44             22                                      48       8
  \[[@B36-ijms-21-04120]\]   Greece        CHT              132                y                                         132         10/122    55                                        19                        13                  12                           7
  \[[@B37-ijms-21-04120]\]   USA           CHT              168                               26          49             243         14/229    206            41 ± 12                    26                        130       50                            136      6
  \[[@B38-ijms-21-04120]\]   USA           CHT                                                34          48             82          17/65     77             27 (21--32)                12                                            50                           7
  \[[@B39-ijms-21-04120]\]   France        CHT              80                                            13       18    111         10/101    111            29 ± 12                               29             54                  21                  35       7
  \[[@B40-ijms-21-04120]\]   Spain         CHT              600                y              y                          600         67/533    600            31 ± 6                     50                        82        51                                     7
  \[[@B41-ijms-21-04120]\]   USA           CHT              106                24                                        130         46/84     130            29.3                       25                        24                                               7
  \[[@B42-ijms-21-04120]\]   MC            CHT              385                157            83                         385         23/249    385            38 ± 10                    32                        73                                               7
  \[[@B43-ijms-21-04120]\]   MCT           CHT                                                            308            308         48/260    308            40 ± 11                    32                        192                 217                 239      6
  \[[@B44-ijms-21-04120]\]   Turkey        CHT              44                                15                         59          6/53      59             35 ± 11                    7                         8         13        21        11        10       7
  \[[@B45-ijms-21-04120]\]   Thailand      CHT                                 41             26                         67          2/65      67             30 ± 10                    28                        39                  59                  18       8
  \[[@B46-ijms-21-04120]\]   USA           CHT              909                y                                         909         0/909     909                                       76                        272       79                                     7
  \[[@B47-ijms-21-04120]\]   USA           CHT              628                y              y                          628         62/566    628            34 ± 12                    65                        149                                     32       7
  \[[@B48-ijms-21-04120]\]   Brazil        CHT              362                y              y                          362         21/341    362            37 ± 12                    44                        39        39                            20       8
  \[[@B49-ijms-21-04120]\]   Mexico        CHT                                                            25/30          55          11/44     55             40 ± 13                    14                        37        50        30        37        23       7
  \[[@B50-ijms-21-04120]\]   Hungary       CHT              119                53             52                         224         20/204    224            49 (20--92)                45                        215                                              6
  \[[@B51-ijms-21-04120]\]   Turkey        CHT              852                y              y                          852         110/742   852            31 ± 12                    93         175            175                                     175      7
  \[[@B52-ijms-21-04120]\]   Brasil        CHT              460                y              y                          460         30/430    460            16--88                     39                        55        53                            59       7
  \[[@B53-ijms-21-04120]\]   MC            CHT              833                604                                       1437        58/1290   1437           30 ± 12                    79                        340       340                                    8
  \[[@B54-ijms-21-04120]\]   Brasil        CHT              373                y                                         373         26/347    373            42 (22--51)                48                        64        49                            56       7
  \[[@B55-ijms-21-04120]\]   Japan         CHT              182                y                                         182         22/160    182            45 ± 14                    10                                                                39       7
  \[[@B56-ijms-21-04120]\]   France        CHT                                                72          28             100         18/82     100            34 (28--39)                9          29             87        87        48        48        90       8
  \[[@B57-ijms-21-04120]\]   Turkey        CHT              725                y              125                        850                   850                                       93         174            24        169                           91       6
  \[[@B58-ijms-21-04120]\]   MC            CHT                                 y              y           y/y            623         164/459   623            44 ± 12                    64                        714       446       530       228       834      8
  \[[@B59-ijms-21-04120]\]   Mexico        CHT                                                            95                         28/67     95             44 ± 14                    8                         54        30        41        20        58       7
  \[[@B60-ijms-21-04120]\]   Egypt         CHT              42                                106                                    13/135    148            23 ± 7                     32                        148                                              6
  **(B)**                                                   **Participants**                                                                                                                                                                                        
  **Studies on AIHA**        **Country**   **Study Type**   **AIHA**           **Non AIHA**   **CTR**                                                                                    **aCL**    **aβ~2~GPI**                                                    
  **Reference**                                             **ID**             **SLE**        **Other**                  **Total**   **M/F**   **Assessed**   **Age**                    **AIHA**   **DAT**        **IgG**   **IgM**   **IgG**   **IgM**   **LA**   **NOS**
                                                            No                 No             No          No       No                                                                                                                                               
  \[[@B61-ijms-21-04120]\]   Mexico        CC               18                                            14             32          19/16     32             33 ± 16                    18         14             7         4                                      7
  \[[@B62-ijms-21-04120]\]   USA           CHT              26                 3              1                          30          11/19     30             43 (21--76)                30                        5         12                            9        7
  \[[@B63-ijms-21-04120]\]   Italy         CC               21                                26                   42    89          9/12      63                                        21                        5                                       6        8
  \[[@B64-ijms-21-04120]\]   China         CC               19                 18                                        37          15/22     37             48 ± 18                    37         37             11                                               6
  -------------------------- ------------- ---------------- ------------------ -------------- ----------- -------- ----- ----------- --------- -------------- -------------------------- ---------- -------------- --------- --------- --------- --------- -------- ---------

Abbreviations. M/F: male/female; AIHA: autoimmune haemolytic anaemia; DAT: direct antiglobulin test; aCL: anticardiolipin; aβ~2~GPI: anti-beta-2-glycoprotein-I; LA: lupus anticoagulant; NOS: Newcastle-Ottawa Scoring; No; number; SLE: systemic lupus erythematosus; CHT: cohort; APS: antiphospholipid syndrome; PAPS: primary antiphospholipid syndrome; CC: case control.
